Aortic Valve Treatment: from mechanical valves, following sutureless bioprosthesis, up to the transcatheter aortic valve implantation

Dear Colleagues,

Waiting for the new guidelines for the valve treatment, the transcatheter aortic valve implantation is indicated up to the low risk patients. However, the heart team decision is the central point for the decision (surgical, minimally invasive, transcatheter). A Special Issue in this field is important to assist the debate in that treatment decisions and reflections.

The topic of interests in this issue include but are not limited to:

- mechanical aortic valve replacement;
- anticoagulant treatment;
- bio-aortic valve replacement;
- new device, new prostheses;
- stented, stentless, sutureless aortic valves;
- transcatheter aortic valves;
- comparing studies;
- follow up studies.

Manuscripts submitted to this Special Issue will be subjected to more stringent selection criteria to ensure the privileged position of accepted contributions. Those that fail to pass this selection will be considered for publication in RCM as regular contributions.

Prof. Dr. Giuseppe Santarpino

Guest Editor(s):

Prof. Dr. Giuseppe Santarpino
gsantarpino@gvmnet.it
Department of Cardiac Surgery, Paracelsus Medical University, Nurnberg, Germany
Department of Experimental and Clinical Medine, Magna Graecia University, Catanzaro, Italy
Message from the Editor-in-Chief

Reviews in Cardiovascular Medicine was launched in 2000 by MedReviews, LLC, in New York, NY. This journal was conceived to fill a critical gap for clinicians who were struggling with a rapidly expanding knowledge base in cardiovascular medicine with the convergence of basic science, clinical epidemiology, and therapeutic clinical trials. The founding co-editors were David P. Faxon, MD, past president of the American Heart Association, and Norman E. Lepor, MD, who is considered a luminary in interventional cardiology. The contributing editorial board grew over time and Dr. Peter A. McCullough, MD, MPH ascended from contributing, to associate, to co-editor of the Journal. In 2018, the Journal took its next big step under the leadership of Dr. McCullough as editor-in-chief to become a truly international publication. Its offices moved to IMR Press in Hong Kong, and the editorial board was made more inclusive and representative of the world-wide contributors in academic cardiology. Additionally, the journal brought on expertise in translational medicine to help face the future of molecular medicine and its role in cardiovascular disease. Today Reviews in Cardiovascular Medicine is considered a top tier journal in cardiology with timely and comprehensive reviews covering all aspects of cardiovascular medicine including atherosclerosis, myocardial disease, arrhythmias, and valvular heart disease. The scope of papers ranges from population science, applied basic investigation, in-vitro diagnostics, and evidence-based strategy and therapeutic trials involving both pharmacologic intervention and interventional devices. The highly integrative style of the Journal anchored with evidence tables and instructive figures has garnered many citations over the years and many guidelines documents have relied upon works published in Reviews in Cardiovascular Medicine. Supplement and focus issues have been very popular among the readership and often are viewed as the most up-to-date compilations of new acknowledge in cardiology and related specialties. The future is bright for academic cardiovascular medicine and Reviews in Cardiovascular Medicine is well positioned along side the clinician-investigator in the years to come as a trusted source of critical information and analysis.

Editor-in-chief:

Dr. Peter A. McCullough

peteramccullough@gmail.com

Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, United States

Submission Deadline: 30 April 2022
Submission: https://jour.ipublishment.com/imr/access/login
Contact us: RCMeditorial@imrpress.org